Ovid Therapeutics Inc. announced the appointment of Ana C. Ward as senior vice president and general counsel. Ms. Ward previously served as general counsel, executive vice president of patient access and corporate development, and board secretary of Rosetta Genomics Ltd. Prior to Rosetta Genomics, Ms. Ward held a series of leadership roles within the Ambion family of companies, including Ambion Inc. (acquired by Applied Biosystems), Asuragen Inc. (a spin-off of Ambion Inc.) and Mirna Therapeutics Inc. (a spin-off of Asuragen Inc.), where she was responsible for managing a diverse portfolio of legal matters such as intellectual property claims, compliance, trademark clearance, and strategic business interactions.